Therapies targeting tumor-specific oncogenic mutations in MM have been unsuccessful, likely because they have been directed to progression events (i.e., MAPK pathway, AKT), which tend to be subclonal due to tumor heterogeneity, and in general are not effective due to the rapid emergence of alternative subclones. This evidence concerns the gene AKT1 and neoplasm.